Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of RC148 plus telisotuzumab adizutecan with or without chemotherapy in unresectable colorectal cancer
CTR20263896Phase 2Active
- Sponsor
- RemeGen
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RC148, telisotuzumab adizutecan in colorectal cancer (CRC), sponsored by RemeGen. Started Oct 2026; status: active.
02
Drugs
RC148telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20263896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263896.